Neil Kirby, Ph.D.
President and Chief Executive Officer
Neil Kirby, Ph.D. is the CEO and President of Phoenix Tissue Repair. Previously, he led Edimer Pharmaceuticals where he has pioneered the use of antenatal therapy in XLHED (X-linked hypohidrotic ectodermal dysplasia), a rare developmental disorder. Dr. Kirby is Chairman of the Board of Orphan Technologies, a company committed to developing first-in-class therapeutics for patients suffering from rare diseases, and brings 30 years of experience working at leading biotechnology companies including Biogen, Genetics Institute / Wyeth, Vertex, TKT / Shire and Stromedix. During this time, he has held positions of increasing responsibility in global regulatory affairs, strategic planning, portfolio management, non-clinical development, manufacturing, and program management. Dr. Kirby has been involved with the development, registration and successful commercial launches of several important therapeutic biopharmaceuticals (including recombinant coagulation factors, cytokines and enzyme replacement therapies). Dr. Kirby received his Ph.D. in the faculty of medicine from the University of London in the UK.